This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
Comparative agents:
Individual ingredients
Indication:
Adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbidity (eg, hypertension, type 2 diabetes mellitus, or dyslipidemia)
Mechanism of action:
Opioid antagonist; aminoketone antidepressant; mechanism for weight control unknown, but may be related to activity in the hypothalamus (appetite regulatory center) and the mesolimbic dopamine circuit (reward system) 
Indication and comments

Recommended for approval by an FDA advisory panel
Aspirin/statin/antihypertensive Potential for a fi xed-combination antihypertensive, aspirin, and statin to reduce the risk of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke in patients with a history of cardiovascular disease (secondary prevention). Committee agreed with the concept to help improvement adherence, but concerns were expressed regarding the ability to achieve recommended target goal for lipid levels and blood pressure.
Recommended for NON-approval by an FDA advisory panel
Nebivolol/valsartan (Forest Laboratories)
Fixed combination (5/160 mg, 10/160 mg, 10/320 mg, and 20/320 mg) for the treatment of hypertension. The committee vote was 6 to 4 recommending against approval. 
Agents scheduled for review by an FDA advisory panel
WARNINGS AND PRECAUTIONS Hypersensitivity Reactions Including Anaphylaxis
• Serious hypersensitivity reactions, including anaphylaxis, have occurred in some patients treated with Elelyso. In clinical trials, 2 of 72 (2.8%) patients treated with Elelyso experienced signs and symptoms consistent with anaphylaxis. Signs and symptoms of these patients included urticaria, hypotension, fl ushing, wheezing, chest tightness, nausea, vomiting, and dizziness. These reactions occurred during Elelyso infusion. • In clinical trials with Elelyso, 21 of 72 (29%) patients experienced hypersensitivity reactions, including anaphylaxis. Signs and symptoms of hypersensitivity reactions included pruritus, angioedema, fl ushing, erythema, rash, nausea, vomiting, cough, chest tightness, and throat irritation. These reactions have occurred up to 3 hours after the start of infusion. • Due to the potential for anaphylaxis, appropriate medical support should be readily available when Elelyso is administered. Observe patients closely for an appropriate period of time after administration of Elelyso, taking into account the time to onset of anaphylaxis seen in clinical trials. Inform patients of the signs and symptoms of anaphylaxis, and instruct them to seek immediate medical care should signs and symptoms occur. If anaphylaxis occurs, Elelyso should be immediately discontinued, and appropriate medical treatment should be initiated. • Management of hypersensitivity reactions should be based on the severity of the reaction and include slowing or temporary interruption of the infusion and/or administration of antihistamines, antipyretics, and/or corticosteroids for mild reactions. Pretreatment with antihistamines and/or corticosteroids may prevent subsequent hypersensitivity reactions. Patients were not routinely premedicated prior to infusion of Elelyso during clinical studies. If severe hypersensitivity reactions occur, immediately stop the infusion of Elelyso and initiate appropriate treatment. • Consider the risks and benefi ts of re-administering Elelyso in patients who have experienced a severe reaction associated with Elelyso. Caution should be exercised upon rechallenge, and appropriate medical support should be readily available. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm413395.htm (continued) 
